Back to Search
MARK LEW, M.D.
M.D.
Neurology Physician
NPI: 1578507505IndividualAccepts Medicare
Education
GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1987
Research & Publications (20)
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
PMID 17407630·Curr Med Res Opin·2007
4-observational
Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
PMID 16274328·Expert Rev Neurother·2005
6-review
Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia.
PMID 14509675·Adv Neurol·2004
4-observational
The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
PMID 11188982·Neurology·2000
3-trial
Interference of a four-hole aperture for on-chip quantitative two-dimensional differential phase imaging.
PMID 17938667·Opt Lett·2007
8-other
Oncologic emergencies: the anesthesiologist's perspective.
PMID 17977499·J Natl Compr Canc Netw·2007
8-other
Histological changes of an injectable rhBMP-2/calcium phosphate cement in vertebroplasty of rhesus monkey.
PMID 19680096·Spine (Phila Pa 1976)·2009
7-preclinical
Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years.
PMID 18425623·J Thromb Thrombolysis·2009
6-review
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
PMID 19086083·Mov Disord·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1520 SAN PABLO ST, SUITE 3000
LOS ANGELES, CA 90033 - Phone
- (323) 442-5710
Quick Facts
- NPI
- 1578507505
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile